Novartis MS drug remibrutinib meets Phase III trial goals
Go back to Novartis MS drug remibrutinib meets Phase III trial goals| NOVARTIS AG (NYSE: NVS) | Delayed: 140.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $140.37 | 52 Week High | $89.15 | |||
| Open | $140.37 | 52 Week Low | $69.84 | |||
| Day High | $140.37 | P/E | N/A | |||
| Day Low | $140.37 | EPS | $0.00 | |||
| Volume | 12,794 | |||||
